Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report

J Voice. 2019 Sep;33(5):716-720. doi: 10.1016/j.jvoice.2018.04.002. Epub 2018 Apr 30.

Abstract

Introduction: Sixty to 90% of patients with idiopathic Parkinson disease (IPD) developed early dysphonia and subtle speech impairment, which is usually related to orofacial muscular dysfunctions. The aim of this preliminary study is to assess the usefulness of voice quality and orofacial strength (involved in speech) as outcome of levodopa challenge test used for the IPD diagnosis.

Material and methods: A total of 20 patients with early IPD were recruited and evaluated for clinical findings (Hoehn and Yahr scale), voice handicap index, maximal phonation time, phonation quotient, percent jitter, percent shimmer, noise-to-harmonic ratio, and orofacial muscular strength (Iowa Oral Performance Instrument) at baseline, throughout the levodopa challenge test and after therapeutic stabilization.

Results: The intake of a standardized dose of levodopa (levodopa challenge test) significantly improved phonation quotient and percent shimmer. We did not find similar improvement after medical stabilization of patients (based on levodopa medication) despite an improvement of Hoehn and Yahr mean score. The intake of levodopa significantly improved cheeks and lips strength involved in speech quality both along the challenge test and after the therapeutic stabilization.

Conclusions: These preliminary findings support a differential impact of levodopa on voice and speech functions in early diagnosed IPD and a mismatch between the clinical examination, orofacial strength, and voice quality improvements once the patient is medically stabilized.

Keywords: Acoustic; IOPI; Parkinson; Speech; Voice.

MeSH terms

  • Antiparkinson Agents / therapeutic use*
  • Dysphonia / diagnosis
  • Dysphonia / drug therapy*
  • Dysphonia / physiopathology
  • Facial Muscles / drug effects*
  • Facial Muscles / physiopathology
  • Humans
  • Levodopa / therapeutic use*
  • Muscle Strength / drug effects*
  • Parkinson Disease / diagnosis
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Phonation / drug effects*
  • Preliminary Data
  • Prospective Studies
  • Recovery of Function
  • Speech Acoustics
  • Time Factors
  • Treatment Outcome
  • Voice Quality / drug effects*

Substances

  • Antiparkinson Agents
  • Levodopa